X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This acquisition is a major milestone to build a robust offering of novel, non-opioid treatments to improve patient care along the neural pain pathway while simultaneously providing a complementary commercial asset in ZILRETTA for the treatment of OA knee pain.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Neurology Product Name: Zilretta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pacira BioSciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 11, 2021
Details:
Company to expand FX201 low dose and mid dose cohorts to include up to 20 additional patients in each treatment group. Clinical data from the first two cohorts indicate that FX201 appears to be generally safe and well-tolerated at the low and mid doses.
Lead Product(s): Humantakinogene hadenovec
Therapeutic Area: Musculoskeletal Product Name: FX201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo.
Lead Product(s): Funapide
Therapeutic Area: Neurology Product Name: FX301
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
Five patients treated in first cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201; Drug Monitoring Committee (DMC) supported the initiation of the next dosing cohort.
Lead Product(s): Humantakinogene hadenovec
Therapeutic Area: Musculoskeletal Product Name: FX201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo.
Lead Product(s): Funapide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Under the terms of the agreement, Flexion will be solely responsible for the manufacture and supply of ZILRETTA to HK Tainuo for all clinical and commercial activities.
Lead Product(s): Omadacycline
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: HK Tainuo
Deal Size: $42.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement April 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
